变构增强剂PD81,723增强了嵌合A1/A2A腺苷受体与Gs的偶联。
The allosteric enhancer PD81,723 increases chimaeric A1/A2A adenosine receptor coupling with Gs.
作者信息
Bhattacharya Samita, Youkey Rebecca L, Ghartey Kobina, Leonard Matthew, Linden Joel, Tucker Amy L
机构信息
Department of Internal Medicine, Cardiovascular Division, University of Virginia Health Sciences Center, Charlottesville, VA 22908, USA.
出版信息
Biochem J. 2006 May 15;396(1):139-46. doi: 10.1042/BJ20051422.
PD81,723 {(2-amino-4,5-dimethyl-3-thienyl)-[3-(trifluromethyl)-phenyl]methanone} is a selective allosteric enhancer of the G(i)-coupled A1 AR (adenosine receptor) that is without effect on G(s)-coupled A2A ARs. PD81,723 elicits a decrease in the dissociation kinetics of A1 AR agonist radioligands and an increase in functional agonist potency. In the present study, we sought to determine whether enhancer sensitivity is dependent on coupling domains or G-protein specificity of the A1 AR. Using six chimaeric A1/A2A ARs, we show that the allosteric effect of PD81,723 is maintained in a chimaera in which the predominant G-protein-coupling domain of the A1 receptor, the 3ICL (third intracellular loop), is replaced with A2A sequence. These chimaeric receptors are dually coupled with G(s) and G(i), and PD81,723 increases the potency of N6-cyclopentyladenosine to augment cAMP accumulation with or without pretreatment of cells with pertussis toxin. Thus PD81,723 has similar functional effects on chimaeric receptors with A1 transmembrane sequences that couple with G(i) or G(s). This is the first demonstration that an allosteric regulator can function in the context of a switch in G-protein-coupling specificity. There is no enhancement by PD81,723 of G(i)-coupled A2A chimaeric receptors with A1 sequence replacing A2A sequence in the 3ICL. The results suggest that the recognition site for PD81,723 is on the A1 receptor and that the enhancer acts to directly stabilize the receptor to a conformational state capable of coupling with G(i) or G(s).
PD81,723{(2-氨基-4,5-二甲基-3-噻吩基)-[3-(三氟甲基)-苯基]甲酮}是一种选择性的G(i)偶联A1腺苷受体(A1 AR)变构增强剂,对G(s)偶联的A2A ARs无作用。PD81,723可使A1 AR激动剂放射性配体的解离动力学降低,功能性激动剂效力增强。在本研究中,我们试图确定增强剂敏感性是否取决于A1 AR的偶联结构域或G蛋白特异性。使用六种嵌合A1/A2A ARs,我们发现,在一种嵌合体中,PD81,723的变构效应得以维持,在该嵌合体中,A1受体的主要G蛋白偶联结构域即第三细胞内环(3ICL)被A2A序列取代。这些嵌合受体与G(s)和G(i)双重偶联,无论细胞是否用百日咳毒素预处理,PD81,723均可增加N6-环戊基腺苷增强环磷酸腺苷(cAMP)积累的效力。因此,PD81,723对具有与G(i)或G(s)偶联的A1跨膜序列的嵌合受体具有相似的功能作用。这是首次证明变构调节剂可在G蛋白偶联特异性切换的情况下发挥作用。PD81,723对3ICL中A1序列取代A2A序列的G(i)偶联A2A嵌合受体没有增强作用。结果表明,PD81,723的识别位点在A1受体上,且该增强剂的作用是直接将受体稳定到能够与G(i)或G(s)偶联的构象状态。